| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -35.0 | -25.2 |
| Net income | -35.1 | -25.2 |
| EPS (diluted, $ a share) | $-0.42 | $-0.48 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: JBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Jade Biosciences, Inc.: key numbers
- Share price
- $15.34Close, Nov 16
- Market cap
- $1.06B
- Shares outstanding
- 69.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Jade Biosciences, Inc.
All →Jade Biosciences Earnings Call: Key Takeaways
Jade Biosciences is advancing its pipeline with Jade 301 for Dermatomyositis, leveraging preclinical data showing 2.5-fold higher affinity and 8-fold greater potency than competitor Dazookibart, with a cash runway extending into Q4 2028.
Jade Biosciences Financial Results
Jade Biosciences reported third quarter 2026 financial results, highlighting a cash position of $476 million which is expected to fund operations into Q4 2028. The company is preparing to initiate its Phase 3 EVERGREEN trial for JADE101 in IgA nephropathy ahead of schedule in Q4 2026.
- Term
- Q3 2026
“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile.”
Tom Frohlich, Chief Executive Officer of Jade
Jade Biosciences Clinical Trial Data
Jade Biosciences announced preclinical data for JADE301, an anti-interferon beta monoclonal antibody being developed for dermatomyositis. The data demonstrated high-affinity binding, potent inhibition of downstream signaling, and a differentiated pharmacokinetic profile supporting infrequent subcutaneous dosing. The company expects to initiate a Phase 1 clinical trial in healthy volunteers in Q4 2026, with interim data anticipated in the second half of 2027.